Ernesto Aycardi

2.0k total citations · 2 hit papers
32 papers, 1.4k citations indexed

About

Ernesto Aycardi is a scholar working on Psychiatry and Mental health, Pathology and Forensic Medicine and Physiology. According to data from OpenAlex, Ernesto Aycardi has authored 32 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Psychiatry and Mental health, 11 papers in Pathology and Forensic Medicine and 10 papers in Physiology. Recurrent topics in Ernesto Aycardi's work include Migraine and Headache Studies (21 papers), Sympathectomy and Hyperhidrosis Treatments (7 papers) and Trigeminal Neuralgia and Treatments (6 papers). Ernesto Aycardi is often cited by papers focused on Migraine and Headache Studies (21 papers), Sympathectomy and Hyperhidrosis Treatments (7 papers) and Trigeminal Neuralgia and Treatments (6 papers). Ernesto Aycardi collaborates with scholars based in United States, United Kingdom and Italy. Ernesto Aycardi's co-authors include Marcelo E. Bigal, David W. Dodick, Paul Yeung, Yuju Ma, Stephen D. Silberstein, Peter J. Goadsby, Ronghua Yang, Melissa Grozinski‐Wolff, Tricia Blankenbiller and Pippa S. Loupe and has published in prestigious journals such as New England Journal of Medicine, JAMA and PLoS ONE.

In The Last Decade

Ernesto Aycardi

32 papers receiving 1.3k citations

Hit Papers

Fremanezumab for the Preventive Treatment of Chronic Migr... 2017 2026 2020 2023 2017 2018 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Fremanezumab for the Preventive Treatment of Chronic Migraine
    2017 544 citations Stephen D. Silberstein, David W. Dodick et al. New England Journal of Medicine profile →
  2. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine
    2018 367 citations David W. Dodick, Stephen D. Silberstein et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ernesto Aycardi United States 14 1.2k 846 509 136 108 32 1.4k
Joe Hirman United States 18 1.5k 1.2× 1.1k 1.3× 675 1.3× 134 1.0× 131 1.2× 53 1.8k
Melissa Grozinski‐Wolff United States 5 1.2k 1.0× 808 1.0× 465 0.9× 123 0.9× 116 1.1× 7 1.2k
Jan Klatt United States 18 1.3k 1.0× 926 1.1× 490 1.0× 120 0.9× 134 1.2× 43 1.4k
Yuju Ma United States 10 1.4k 1.2× 1.0k 1.2× 614 1.2× 154 1.1× 116 1.1× 21 1.7k
Bianca Raffaelli Germany 22 1.2k 1.0× 694 0.8× 364 0.7× 134 1.0× 206 1.9× 69 1.4k
David Doležil United States 10 914 0.8× 657 0.8× 336 0.7× 90 0.7× 103 1.0× 27 992
Tricia Blankenbiller United States 4 893 0.7× 620 0.7× 367 0.7× 102 0.8× 87 0.8× 8 962
Lars Neeb Germany 26 1.3k 1.0× 667 0.8× 480 0.9× 226 1.7× 151 1.4× 72 1.7k
Jo Bonner United States 8 782 0.6× 522 0.6× 297 0.6× 94 0.7× 63 0.6× 11 868
Kevin Shields United Kingdom 11 695 0.6× 496 0.6× 378 0.7× 144 1.1× 87 0.8× 14 885

Countries citing papers authored by Ernesto Aycardi

Since Specialization
Citations

This map shows the geographic impact of Ernesto Aycardi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ernesto Aycardi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ernesto Aycardi more than expected).

Fields of papers citing papers by Ernesto Aycardi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ernesto Aycardi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ernesto Aycardi. The network helps show where Ernesto Aycardi may publish in the future.

Co-authorship network of co-authors of Ernesto Aycardi

This figure shows the co-authorship network connecting the top 25 collaborators of Ernesto Aycardi. A scholar is included among the top collaborators of Ernesto Aycardi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ernesto Aycardi. Ernesto Aycardi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hammer, Michael F., John M. Schreiber, Celene Grayson, et al.. (2022). Clinical characteristics and treatment experience of individuals with SCN8A developmental and epileptic encephalopathy (SCN8A-DEE): Findings from an online caregiver survey. Seizure. 97. 50–57. 9 indexed citations
2.
Lipton, Richard B., Joshua M. Cohen, Maja Galić, et al.. (2021). Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study. Headache The Journal of Head and Face Pain. 61(4). 662–672. 33 indexed citations
3.
Grayson, Celene, et al.. (2021). Evaluating the Epidemiological Burden of KCNQ2 Epilepsy (5169). Neurology. 96(15_supplement). 1 indexed citations
4.
Millichap, J Gordon, Cynthia L. Harden, Dennis Dlugos, et al.. (2021). Capturing seizures in clinical trials of antiseizure medications for KCNQ2‐DEE. Epilepsia Open. 6(1). 38–44. 4 indexed citations
5.
6.
7.
8.
Brandes, Jan Lewis, David Kudrow, Paul Yeung, et al.. (2019). Effects of fremanezumab on the use of acute headache medication and associated symptoms of migraine in patients with episodic migraine. Cephalalgia. 40(5). 470–477. 13 indexed citations
9.
Winner, Paul, Egilius L.H. Spierings, Paul Yeung, et al.. (2019). Early Onset of Efficacy With Fremanezumab for the Preventive Treatment of Chronic Migraine. Headache The Journal of Head and Face Pain. 59(10). 1743–1752. 31 indexed citations
10.
Lipton, Richard B., Sanjay Gandhi, Timothy Fitzgerald, et al.. (2018). The Positive Impact of Fremanezumab on Work Productivity and Activity Impairment in Patients with Chronic Migraine (S32.007). Neurology. 90(15_supplement). 1 indexed citations
11.
Winner, Paul, Timothy Fitzgerald, Sanjay Gandhi, et al.. (2018). The Impact of Fremanezumab on Headache-Related Disability in Patients with Episodic Migraine using the Migraine Disability Assessment (P4.095). Neurology. 90(15_supplement). 1 indexed citations
12.
Brandes, Jan Lewis, Paul Yeung, Ernesto Aycardi, et al.. (2018). Early Onset of Action with Fremanezumab Versus Placebo for the Preventive Treatment of Episodic Migraine (P4.107). Neurology. 90(15_supplement). 3 indexed citations
13.
Singh, Rashmi B. Halker, Ernesto Aycardi, Marcelo E. Bigal, et al.. (2018). Sustained reductions in migraine days, moderate-to-severe headache days and days with acute medication use for HFEM and CM patients taking fremanezumab: Post-hoc analyses from phase 2 trials. Cephalalgia. 39(1). 52–60. 24 indexed citations
14.
Yeung, Paul, Ernesto Aycardi, Marcelo E. Bigal, et al.. (2018). Early Onset of Action with Fremanezumab Versus Placebo for the Preventive Treatment of Chronic Migraine (P4.102). Neurology. 90(15_supplement). 2 indexed citations
15.
Bigal, Marcelo E., Alan M. Rapoport, Stephen D. Silberstein, et al.. (2018). From LBR-101 to Fremanezumab for Migraine. CNS Drugs. 32(11). 1025–1037. 13 indexed citations
16.
Lipton, Richard B., Sanjay Gandhi, Timothy Fitzgerald, et al.. (2018). The Impact of Fremanezumab on Migraine-Specific Health-Related Quality of Life in Episodic Migraine (P4.115). Neurology. 90(15_supplement). 1 indexed citations
17.
Silberstein, Stephen D., David W. Dodick, Marcelo E. Bigal, et al.. (2017). Fremanezumab for the Preventive Treatment of Chronic Migraine. New England Journal of Medicine. 377(22). 2113–2122. 544 indexed citations breakdown →
18.
Gajria, Kavita, Lulu K. Lee, Natalia M. Flores, Ernesto Aycardi, & Sanjay Gandhi. (2017). Humanistic and economic burden of nausea and vomiting among migraine sufferers. Journal of Pain Research. Volume 10. 689–698. 22 indexed citations
19.
Krupp, Lauren, Daniela Pohl, Angelo Ghezzi, et al.. (2016). Subcutaneous interferon β-1a in pediatric patients with multiple sclerosis: Regional differences in clinical features, disease management, and treatment outcomes in an international retrospective study. Journal of the Neurological Sciences. 363. 33–38. 20 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Joe Hirman Breakdown of academic impact, for papers by Melissa Grozinski‐Wolff Breakdown of academic impact, for papers by Jan Klatt Breakdown of academic impact, for papers by Yuju Ma Breakdown of academic impact, for papers by Bianca Raffaelli Breakdown of academic impact, for papers by David Doležil Breakdown of academic impact, for papers by Tricia Blankenbiller Breakdown of academic impact, for papers by Lars Neeb Breakdown of academic impact, for papers by Jo Bonner Breakdown of academic impact, for papers by Kevin Shields
Rankless by CCL
2026